News : Diamyd Inc.

First quarter report for Diamyd Medical AB (publ), fiscal year 2009/2010
(www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY)
First quarter, September 1 – November 30, 2009

• The last patient was included in the European Phase III study of the Diamyd® diabetes vaccine.

• The US Department of Veterans Affairs (VA) awarded a grant of USD 1.84 million to support the development of Diamyd’s Nerve...

Diamyd Inc, Pittsburgh, PA, USA, a wholly-owned subsidiary of Diamyd Medical, Stockholm Sweden, announces today that the United States Department of Veterans Affairs (VA) has awarded a $1.84 million grant to support the development of Diamyd’s Nerve Targeting Drug Delivery System (NTDDS) for Diabetic Neuropathic Pain.
The two-year grant largely funds the advancement of NTDDS with Glutamic Acid Decarboxylase...